Form 8-K

8-K — HeartSciences Inc.

Accession: 0001213900-26-081007

Filed: 2026-07-23

Period: 2026-07-23

CIK: 0001468492

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0299113-8k_heart.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED JULY 23, 2026 (ea029911301ex99-1.htm)

GRAPHIC (ea029911301_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0299113-8k_heart.htm · Sequence: 1

false

0001468492

2026-07-23

0001468492

us-gaap:CommonStockMember

2026-07-23

0001468492

HSCS:WarrantsMember

2026-07-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 23, 2026

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its

Charter)

Texas

001-41422

26-1344466

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

550 Reserve Street, Suite 360

Southlake, Texas

76092

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including

Area Code: (682) 237-7781

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

HSCS

The Nasdaq Stock Market LLC

Warrants

HSCSW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On July 23, 2026, HeartSciences

Inc., a Texas corporation (“HeartSciences”), issued a press release announcing the filing of its Annual Report on Form

10-K for the fiscal year ended April 30, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) and commenting

that it expects to file shortly with the SEC a preliminary proxy statement in connection with its recently announced proposed Transactions

(as defined below), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”).

As previously reported, on

June 23, 2026, HeartSciences, Fortitude Mining Holdings, Inc., a Delaware corporation (“Seller”), Fortitude Mining

HoldCo, LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of Seller (“Fortitude”), and

Cordis Acquisition, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Parent (“Merger Sub”),

entered into an Agreement and Plan of Merger (the “Merger Agreement”).

The information provided in

this Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the

liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of HeartSciences under the

Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date

hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference

in such filing.

Additional Information and Where to Find It

HeartSciences intends to file

with the SEC a proxy statement (together with any amendments or supplements thereto, the “Proxy Statement”) to in connection

with the transactions contemplated by the Merger Agreement (the “Transactions”). The definitive Proxy Statement and

other relevant documents will be mailed to stockholders of HeartSciences as of a record date to be established for voting on the Transactions

and other matters as described in the Proxy Statement. HeartSciences will also file other documents regarding the Transactions with the

SEC. This Current Report does not contain all of the information that should be considered concerning the Transactions and is not intended

to form the basis of any investment decision or any other decision in respect of the Transactions. BEFORE MAKING ANY VOTING OR INVESTMENT

DECISION, STOCKHOLDERS OF HEARTSCIENCES AND OTHER INTERESTED PARTIES ARE URGED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT,

AND AMENDMENTS THERETO, AND THE DEFINITIVE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN

CONNECTION WITH HEARTSCIENCES’ SOLICITATION OF PROXIES FOR THE SPECIAL MEETING OF ITS STOCKHOLDERS TO BE HELD TO APPROVE THE TRANSACTIONS

AND OTHER MATTERS AS DESCRIBED IN THE PROXY STATEMENT BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND

FORTITUDE AND THE TRANSACTIONS. Investors and security holders will also be able to obtain copies of the Proxy Statement and all other

documents filed or that will be filed with the SEC by HeartSciences, without charge, once available, on the SEC’s website at www.sec.gov.

NEITHER THE SEC NOR ANY STATE

SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE

TRANSACTIONS OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS CURRENT REPORT. ANY REPRESENTATION

TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Participants in the Solicitation

HeartSciences, Fortitude,

Seller and their respective directors, executive officers, and certain executive officers of Digital Currency Group, Inc. may be deemed

under SEC rules to be participants in the solicitation of proxies from HeartSciences’ stockholders in connection with the Transactions.

A list of the names of such persons, and information regarding their interests in the Transactions and their ownership of HeartSciences’

securities are, or will be, contained in HeartSciences’ filings with the SEC, including HeartSciences’ Annual Report on Form

10-K for the year ended April 30, 2026 filed with the SEC on July 23, 2026. Additional information regarding the interests of the persons

who may, under SEC rules, be deemed participants in the solicitation of proxies of HeartSciences’ stockholders in connection with

the Transactions, including the names and interests of Fortitude’s directors and executive officers, will be set forth in the Proxy

Statement and other relevant materials, which are expected to be filed by HeartSciences with the SEC when they become available. Investors

and security holders may obtain free copies of these documents as described above.

No Offer or Solicitation

The information contained

in this Current Report and the exhibits filed or furnished herewith are for informational purposes only and are not a proxy statement

or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transactions and shall not constitute

an offer to sell or exchange, or a solicitation of an offer to buy or exchange the securities of HeartSciences, or any commodity or instrument

or related derivative, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation,

sale or exchange would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No

offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom.

Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the

Securities Act.

Item 9.01 Financial Statements and Exhibits

(a) Exhibits

Number

Description

99.1*

Press Release, dated July 23, 2026.

104*

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Furnished

herewith.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEARTSCIENCES INC.

Date: July 23, 2026

By:

/s/ Andrew Simpson

Name:

Andrew Simpson

Title:

President, Chief Executive Officer and Chairman of the Board of Directors

EX-99.1 — PRESS RELEASE, DATED JULY 23, 2026

EX-99.1

Filename: ea029911301ex99-1.htm · Sequence: 2

Exhibit 99.1

HeartSciences Files Its Fiscal 2026 Annual Report

on Form 10-K

Company believes proposed Fortitude merger represents a significant

opportunity for the Company’s shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to

be filed shortly, with fiscal 2026 earnings release and business update to follow

Southlake, TX, July 23, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.

(Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company

focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”),

today announced that it has filed its Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended April 30, 2026

(“fiscal 2026”) with the U.S. Securities and Exchange Commission (the “SEC”). The Form 10-K is available at www.sec.gov

and on the Company’s website at www.heartsciences.com.

The Company also expects to file shortly with the SEC a preliminary

proxy statement in connection with its recently announced proposed business combination and related transactions (the “Proposed

Transaction”) with Fortitude Mining Holdings, Inc. (“Fortitude”), an institutional-scale, vertically integrated venture

mining platform operating across the Proof-of-Work ecosystem and anchored in Zcash, currently wholly-owned by Digital Currency Group (“DCG”).

The Company believes the Proposed Transaction represents a significant opportunity for its shareholders, providing continued ownership

in a business operating at scale, generating meaningful revenue and backed by an established investor, while enabling the Company’s

MyoVista Insights AI-ECG technology to keep advancing with greater focus.

Following the filing of the preliminary proxy statement, the Company

intends to issue its fiscal 2026 earnings release and a business update, currently expected early next week.

“Fiscal 2026 was a landmark year for HeartSciences, with the launch

of MyoVista Insights and the beginning of our transition to mainstream commercial revenue,” said Andrew Simpson, the CEO of HeartSciences.

“We also believe the proposed business combination with Fortitude represents a significant value creation opportunity for our shareholders.

The proxy statement will set out the transaction in detail, and we look forward to discussing our results, the proposed merger and the

path ahead in our full earnings statement and business update early next week.”

For more information, please visit: https://www.heartsciences.com.

X: @HeartSciences

About Fortitude

Fortitude, currently wholly-owned by DCG,

is an institutional-scale, vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in

Zcash. Fortitude pairs self-mining operations with an owned data center footprint, a diversified power portfolio backed by competitive

long-term contracts, and disciplined capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work

ecosystems, beginning with its meaningful position in the Zcash network. Fortitude is led by an experienced team of operators, capital

markets professionals, and digital asset specialists with a track record of identifying and scaling high-conviction opportunities and

building privacy-preserving digital asset infrastructure.

For more information, visit www.fortitudemining.com and follow Fortitude

on X at @FortitudeCrypto

About HeartSciences

HeartSciences is a healthcare information technology company advancing

the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ Platform is a device-agnostic,

next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed

to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.

For more information, please visit: www.heartsciences.com and follow

HeartSciences on X at @HeartSciences

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements concerning HeartSciences,

Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally can be identified by the use of words

such as “aim,” “anticipate,” “expect,” “plan,” “could,” “may,”

“will,” “believe,” “estimate,” “forecast,” “goal,” “project,”

“potential,” “target,” “objective,” “intend,” and other words of similar meaning, but

the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not

limited to, express or implied statements relating to timing and contents of future HeartSciences’ SEC filings and earnings announcements

and HeartSciences’ management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including,

without limitation, statements regarding the Proposed Transaction and its expected effects, perceived benefits or opportunities, including

related to value creation. All statements contained in this press release that do not relate to matters of historical fact should be considered

forward-looking statements.

These forward-looking statements are based on management’s current

expectations and assumptions as of the date of this press release and are subject to a number of known and unknown risks, uncertainties,

and other factors that could cause actual results to differ materially from those expressed or implied by such statements, including,

without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all;

the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of the HeartSciences’

shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined

company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude’s

operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; and risks relating to

significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally. Additional factors that may cause

actual results to differ materially from those expressed or implied by the forward-looking statements in this press release are discussed

in HeartSciences’ filings with the SEC, including its most recent Annual Report on Form 10-K, filed with the SEC on July 23, 2026,

Quarterly Reports on Form 10-Q, and other reports filed with the SEC from time to time, and will be discussed in the proxy statement to

be filed by HeartSciences with the SEC in connection with the Proposed Transaction. Readers are cautioned not to place undue reliance

on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise any forward-looking

statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. All forward-looking

statements are made as of the date of this press release.

Additional Information About the Proposed Transaction and Where

to Find It

This press release may be deemed solicitation material in respect of

the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences intends to file relevant materials with the SEC,

including a preliminary proxy statement on Schedule 14A. Following the filing of a definitive proxy statement with the SEC, HeartSciences

will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the

Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS

OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES WILL FILE WITH

THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. THIS

PRESS RELEASE DOES NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS AND

IS NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The preliminary

proxy statement, the definitive proxy statement and other relevant materials in connection with the Proposed Transaction (when they become

available), and any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at

www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed with the SEC or by sending a request

to the HeartSciences’ Investor Relations Department at investorrelations@heartsciences.com.

Participants in the Solicitation

HeartSciences and Fortitude, their respective directors and executive

officers, and certain executive officers of DCG may be deemed to be participants in the solicitation of proxies from HeartSciences’

shareholders with respect to the Proposed Transaction. Information about HeartSciences’ directors and executive officers and their

ownership of HeartSciences’ common stock is set forth in HeartSciences’ proxy statement for its 2026 Annual Meeting of Stockholders,

which was filed with the SEC on March 17, 2026. Information regarding the identity of the potential participants, and their direct or

indirect interests in the Proposed Transaction, by security holdings or otherwise, will be set forth in the proxy statement and other

materials to be filed with the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

This press release and the information contained herein is not intended

to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise

acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction,

pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction

in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the merger

agreement, which contain the full terms and conditions of the Proposed Transaction.

Investor Relations:

Integrous Communications

Mark Komonoski, Partner

Phone: 877 255 8483

Email: mkomonoski@integcom.us

GRAPHIC

Filename: ea029911301_ex99-1img1.jpg · Sequence: 3

Binary file (5091 bytes)

Download ea029911301_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jul. 23, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 23, 2026

Entity File Number

001-41422

Entity Registrant Name

HEARTSCIENCES INC.

Entity Central Index Key

0001468492

Entity Tax Identification Number

26-1344466

Entity Incorporation, State or Country Code

Entity Address, Address Line One

550 Reserve Street

Entity Address, Address Line Two

Suite 360

Entity Address, City or Town

Southlake

Entity Address, State or Province

Entity Address, Postal Zip Code

76092

City Area Code

682

Local Phone Number

237-7781

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

HSCS

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

HSCSW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HSCS_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: